Blueprint Medicines Corp Collaboration Agreements
11 Contracts & Agreements
- Amendment No. 2 to Collaboration and License Agreement, dated as of July 27, 2023, between Blueprint Medicines Corporation and Oncopia Therapeutics, Inc. d/b/a Proteovant... (Filed With SEC on August 2, 2023)
- Amendment No. 1 to Collaboration and License Agreement, dated as of June 5, 2023, between Blueprint Medicines Corporation and Oncopia Therapeutics, Inc. d/b/a Proteovant... (Filed With SEC on August 2, 2023)
- Tenth Amendment to Collaboration and License Agreement, effective August 4, 2016, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and the Registrant (Filed With SEC on May 3, 2022)
- Collaboration and License Agreement dated as of February 26, 2022 by and between Oncopia Therapeutics, Inc., d/b/a Proteovant Therapeutics, Inc. and the Registrant (Filed With SEC on May 3, 2022)
- Ninth Amendment to Collaboration and License Agreement, effective January 8, 2021, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and the Registrant (Filed With SEC on February 17, 2021)
- Eighth Amendment to Collaboration and License Agreement, effective April 30, 2020, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and Blueprint Medicines Corporation (Filed With SEC on May 6, 2020)
- Seventh Amendment to Collaboration and License Agreement, effective December 17, 2019, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and Blueprint Medicines... (Filed With SEC on December 20, 2019)
- Sixth Amendment to Collaboration and License Agreement, effective November 1, 2019, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and Blueprint Medicines... (Filed With SEC on November 5, 2019)
- Fifth Amendment to Collaboration and License Agreement, effective June 28, 2019, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and Blueprint Medicines Corporation (Filed With SEC on July 3, 2019)
- Fourth Amendment to Collaboration and License Agreement, effective February 25, 2019, by and among F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc. and the Registrant (Filed With SEC on February 26, 2019)
- THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 10, 2016)
